SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001390478-23-000020
Filing Date
2023-08-10
Accepted
2023-08-10 16:12:18
Documents
13
Period of Report
2023-08-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sls-20230810.htm   iXBRL 8-K 32572
2 EX-99.1 sls-202308108xkexhibit991.htm EX-99.1 92603
  Complete submission text file 0001390478-23-000020.txt   265781

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sls-20230810.xsd EX-101.SCH 1931
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sls-20230810_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sls-20230810_pre.xml EX-101.PRE 13067
7 EXTRACTED XBRL INSTANCE DOCUMENT sls-20230810_htm.xml XML 2826
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 231159499
SIC: 2834 Pharmaceutical Preparations